This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mendes, R. E.
Right arrow Articles by Jones, R. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mendes, R. E.
Right arrow Articles by Jones, R. N.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2008, p. 2244-2246, Vol. 52, No. 6
0066-4804/08/$08.00+0     doi:10.1128/AAC.00231-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

First Report of cfr-Mediated Resistance to Linezolid in Human Staphylococcal Clinical Isolates Recovered in the United States {triangledown}

Rodrigo E. Mendes,1 Lalitagauri M. Deshpande,1 Mariana Castanheira,1 Joseph DiPersio,2 Michael A. Saubolle,3 and Ronald N. Jones1*

JMI Laboratories, North Liberty, Iowa,1 Summa Health System, Akron, Ohio,2 Laboratory Sciences of Arizona, Banner Health, Phoenix, Arizona3

Received 19 February 2008/ Returned for modification 5 March 2008/ Accepted 30 March 2008


arrow
ABSTRACT
 
Linezolid resistance has dominantly been mediated by mutations in 23S rRNA or ribosomal protein L4 genes. Recently, cfr has demonstrated the ability to produce a phenotype of resistance to not only oxazolidinones, but also other antimicrobial classes (phenicols, lincosamides, pleuromutilins, and streptogramin A). We describe the first detection of cfr-mediated linezolid resistance in Staphylococcus aureus and Staphylococcus epidermidis recovered from human infection cases monitored during the 2007 LEADER Program.


arrow
TEXT
 
Linezolid, the first oxazolidinone class agent used in clinical practice, has demonstrated potent antimicrobial activity against gram-positive pathogens, including methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, and Streptococcus spp. (3). According to the LEADER Program (5), nearly all S. aureus strains (>99.9%) and coagulase-negative staphylococci (98.4%) isolated in the United States were susceptible to linezolid. Furthermore, similar results (99.8% susceptibility) were observed when testing a global collection of gram-positive isolates evaluated by the ZAAPS Program in the same year (5, 6). Linezolid resistance has appeared only sporadically since its introduction in 2000, and it is usually mediated by the presence of mutations in one or more alleles of the target 23S rRNA gene (4, 11). However, some linezolid-resistant isolates fail to display these mutations, indicating the presence of other resistance mechanisms.

Previously, the cfr gene was described as a chloramphenicol resistance mechanism in Staphylococcus sciuri (14). The cfr-encoded product, a methyltransferase, provides posttranscriptional methylation of the 23S rRNA at position A2503. This methylation affects the binding of at least four antimicrobial classes (phenicols, lincosamides, pleuromutilins, and streptogramin A), leading to a multidrug-resistant phenotype (10). This gene has been detected in Staphylococcus spp. of animal origin in Europe (7, 8, 10, 14). One recent report described the detection of cfr in a Staphylococcus aureus isolate recovered from the respiratory tract of an infected patient in Colombia (16).

The LEADER Program evaluates the activity of linezolid and numerous comparator agents against gram-positive clinical isolates recovered from more than 50 medical centers within the United States. During the 2007 LEADER Program, linezolid-resistant S. aureus (004-737X) and Staphylococcus epidermidis (426-3147L) were forwarded to JMI Laboratories (North Liberty, IA) and tested for susceptibility by the Clinical and Laboratory Standards Institute (CLSI) reference broth microdilution method (1). The S. aureus strain was isolated from a 45-year-old paraplegic female patient residing in a nursing home. She was admitted to a hospital in Ohio showing symptoms of urinary tract infection, pneumonia, and sepsis, which required mechanical ventilation. Candida spp. were recovered from a blood culture, and the patient received an antifungal agent plus ciprofloxacin therapy. Pseudomonas spp. were also recovered from a urine culture. S. aureus (004-737X), Klebsiella pneumoniae, and Pseudomonas alcaligenes were recovered from a bronchio-alveolar lavage specimen. The patient subsequently received azithromycin, vancomycin, linezolid, and piperacillin-tazobactam and remained hospitalized for 1 month secondary to respiratory failure. S. epidermidis (426-3147L) was isolated from a 79-year-old female living in a long-term care facility. Between July and September 2007, she was admitted to a hospital in Arizona and returned to the long-term care facility multiple times before being placed in hospital care. S. epidermidis was recovered from a blood culture 3 days after the second hospital admission. She received vancomycin, cefepime, and ampicillin/sulbactam. No linezolid use could be documented.

Both isolates (004-737X and 426-3147L) displayed linezolid-nonsusceptible phenotypes (MICs of 8 and >256 µg/ml, respectively), which were confirmed by the Etest (AB Biodisk, Solna, Sweden) and the disk diffusion methods (2), with results at 8 and >256 µg/ml or 19 and 6 mm, respectively. Additionally, the isolates showed resistance to chloramphenicol, clindamycin, quinupristin-dalfopristin, retapamulin, oxacillin, ciprofloxacin, erythromycin (S. aureus only), tetracycline, and trimethoprim-sulfamethoxazole but remained susceptible to vancomycin (Table 1). These results led to screenings for the G2576T mutation in the 23S rRNA genes (11) and the previously described cfr gene (8). The G2576T mutation was not present, but a positive PCR result was obtained using cfr-specific primers, which was confirmed in both isolates by sequencing. S. aureus 004-737X was further analyzed for the characterization of SCCmec types and the presence of PVL genes (lukF-PV and lukS-PV) (12) and was subjected to pulsed-field gel electrophoresis (PFGE). The PFGE pattern was compared to those of contemporary community-acquired and hospital-associated methicillin-resistant S. aureus clones prevalent in the United States (15). Additionally, both isolates were screened for erythromycin resistance determinants, as previously described (9). Characterization of SCCmec types (I through VI) of S. aureus isolate 004-737X was unsuccessful, and the reaction for the presence of PVL genes was negative. The isolate showed a unique PFGE pattern compared to those of the predominant U.S. clones, and erythromycin resistance in the isolate 004-737X was mediated by ermA, while the isolate 426-3147L showed negative results for the most common ermA, ermB, ermC, and mefA resistance genes. This latter result does not exclude the possibility that the isolate 426-3147L harbored other ribosomal methylation or efflux pump genes, which could explain the decreased susceptibility (4 µg/ml) to erythromycin.


View this table:
[in this window]
[in a new window]

  		TABLE 1. Antimicrobial susceptibility profiles of cfr-harboring S. aureus (004-737X) and S. epidermidis (426-3147L) isolates

Plasmid DNA was extracted using the plasmid DNA midi kit (Qiagen GmbH, Hilden, Germany), separated on 1% agarose gel in Tris-acetate-EDTA buffer on a Criterion sub-cell GT system (Bio-Rad, Hercules, CA), and transferred onto a nylon membrane by Southern blotting (13). A labeled cfr probe was used for hybridization, which was revealed with a nonradioactive DIG-High Prime DNA labeling and detection kit (Roche Diagnostics GmbH, Mannheim, Germany). Plasmid sizes were determined by comparison with standard plasmid DNAs extracted from Escherichia coli NCTC 50192 and NCTC 50193. Analysis of the plasmid content of isolates 004-737X and 426-3147L revealed the presence of two plasmids in each isolate (550 and 55 kb, and 175 and 75 kb, respectively). Experiments showed that the 55- and 175-kb plasmid DNAs from isolates 004-737X and 426-3147L, respectively, hybridized with the cfr-specific probe (data not shown).

Surrounding cfr DNA sequences were accessed by primer walking. Downstream of the cfr gene, the presence of {Delta}tnpB was noted in the S. aureus isolate, which was identical to the structure described for the pSCFS3 plasmid found in an S. aureus isolate collected from the respiratory tract of a swine (7) (AM086211) (Fig. 1). The DNA sequence upstream of the cfr gene in the S. aureus isolate showed the presence of istAS and istBS genes, which were also identical to those of the pSCFS3 plasmid, suggesting that these insertion sequences may be involved in the mobilization of the cfr gene (7). However, a PCR using a primer targeting {Delta}tnpA (tnpA-F), which was located further upstream of the cfr gene on the pSCFS3 plasmid, yielded a negative result, suggesting that the upstream region of cfr on this isolate significantly differed from that of the pSCFS3 plasmid. PCRs performed with the primers cfr-F and cfr-R2 or cfr-F2 and tnpB-R for the 426-3147L isolate yielded negative results, also indicating additional distinct DNA sequences upstream and downstream of the cfr gene on this isolate. Further analysis of the cfr genetic context in the 426-3147L isolate is ongoing.


Figure 1
View larger version (27K):
[in this window]
[in a new window]

  		FIG. 1. Schematic representation of cfr surrounding DNA sequences in S. aureus (004-737X) and S. epidermidis (426-3147L) isolates. The genetic context of pSCFS3 is also shown for comparison purposes (AM086211). Genes are indicated by boxes, and the arrows indicate their transcriptional orientations. Small arrows indicate primers targeting regions and their respective orientations. Dashes indicate unknown DNA sequences. The background shading indicates identity to the pSCFS3 DNA sequence.

Linezolid resistance, as described in numerous earlier reports, has been mediated by mutations in 23S rRNA or other ribosomal protein genes, implying the slow dissemination of resistance by these mechanisms (10). However, the detection of a plasmid-borne cfr-mediated linezolid resistance gene in staphylococci recovered from human specimens in the United States adds a new dimension to the threat against the clinical utility of several antimicrobial classes, including the oxazolidinones.

Although S. aureus 004-737X did not belong to one of the prevalent clones in the United States (15) and cfr-carrying Staphylococcus sp. isolates appear rare (10), these data require continued active resistance surveillance programs (such as LEADER and ZAAPS). This must be combined with effective infection control strategies in case further spread of this resistance mechanism is observed by those programs. The dissemination of the cfr-mediated resistance genes among staphylococcal clinical isolates is especially worrisome given the potential for rapid simultaneous increases in resistance rates for several antimicrobial classes.

Nucleotide sequence accession number. The nucleotide sequences of the cfr gene from S. aureus 004-737X have been deposited in the GenBank database under the accession number EU598691.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317. Phone: (319) 665-3370. Fax: (319) 655-3371. E-mail: ronald-jones{at}jmilabs.com Back

{triangledown} Published ahead of print on 7 April 2008. Back


arrow
REFERENCES
 
    1
  1. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A7, 7th edition. CLSI, Wayne, PA.
    2. 2
  2. Clinical and Laboratory Standards Institute. 2007. Performance standards for antimicrobial susceptibility testing; 17th informational supplement. M100-S17. CLSI, Wayne, PA.
    3. 3
  3. Diekema, D. J., and R. N. Jones. 2001. Oxazolidinone antibiotics. Lancet 358:1975-1982.[CrossRef][Medline]
    4. 4
  4. Farrell, D. J., I. Morrissey, S. Bakker, S. Buckridge, and D. Felmingham. 2004. In vitro activities of telithromycin, linezolid, and quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations. Antimicrob. Agents Chemother. 48:3169-3171.[Abstract/Free Full Text]
    5. 5
  5. Jones, R. N., T. R. Fritsche, H. S. Sader, and J. E. Ross. 2007. LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers). Diagn. Microbiol. Infect. Dis. 59:309-317.[Medline]
    6. 6
  6. Jones, R. N., T. R. Fritsche, H. S. Sader, and J. E. Ross. 2007. Zyvox Annual Appraisal of Potency and Spectrum Program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries. Diagn. Microbiol. Infect. Dis. 59:199-209.[CrossRef][Medline]
    7. 7
  7. Kehrenberg, C., F. M. Aarestrup, and S. Schwarz. 2007. IS21-558 insertion sequences are involved in the mobility of the multiresistance gene cfr. Antimicrob. Agents Chemother. 51:483-487.[Abstract/Free Full Text]
    8. 8
  8. Kehrenberg, C., and S. Schwarz. 2006. Distribution of florfenicol resistance genes fexA and cfr among chloramphenicol-resistant Staphylococcus isolates. Antimicrob. Agents Chemother. 50:1156-1163.[Abstract/Free Full Text]
    9. 9
  9. Lina, G., A. Quaglia, M. E. Reverdy, R. Leclercq, F. Vandenesch, and J. Etienne. 1999. Distribution of genes encoding resistance to macrolides, lincosamides, and streptogramins among staphylococci. Antimicrob. Agents Chemother. 43:1062-1066.[Abstract/Free Full Text]
    10. 10
  10. Long, K. S., J. Poehlsgaard, C. Kehrenberg, S. Schwarz, and B. Vester. 2006. The Cfr rRNA methyltransferase confers resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A antibiotics. Antimicrob. Agents Chemother. 50:2500-2505.[Abstract/Free Full Text]
    11. 11
  11. Meka, V. G., S. K. Pillai, G. Sakoulas, C. Wennersten, L. Venkataraman, P. C. DeGirolami, G. M. Eliopoulos, R. C. Moellering, Jr., and H. S. Gold. 2004. Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA. J. Infect. Dis. 190:311-317.[CrossRef][Medline]
    12. 12
  12. Mendes, R. E., H. S. Sader, L. Deshpande, and R. N. Jones. 2008. Antimicrobial activity of tigecycline against community-acquired methicillin-resistant Staphylococcus aureus isolates recovered from North American medical centers. Diagn. Microbiol. Infect. Dis. 60:433-436.[Medline]
    13. 13
  13. Sambrook, J., P. MacCallum, and D. Russell. 2001. Molecular cloning: a laboratory manual, 3rd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
    14. 14
  14. Schwarz, S., C. Werckenthin, and C. Kehrenberg. 2000. Identification of a plasmid-borne chloramphenicol-florfenicol resistance gene in Staphylococcus sciuri. Antimicrob. Agents Chemother. 44:2530-2533.[Abstract/Free Full Text]
    15. 15
  15. Tenover, F. C., L. K. McDougal, R. V. Goering, G. Killgore, S. J. Projan, J. B. Patel, and P. M. Dunman. 2006. Characterization of a strain of community-associated methicillin-resistant Staphylococcus aureus widely disseminated in the United States. J. Clin. Microbiol. 44:108-118.[Abstract/Free Full Text]
    16. 16
  16. Toh, S. M., L. Xiong, C. A. Arias, M. V. Villegas, K. Lolans, J. Quinn, and A. S. Mankin. 2007. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol. Microbiol. 64:1506-1514.[CrossRef][Medline]

Antimicrobial Agents and Chemotherapy, June 2008, p. 2244-2246, Vol. 52, No. 6
0066-4804/08/$08.00+0     doi:10.1128/AAC.00231-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Sierra, J. M., Ortega, M., Tarrago, C., Albet, C., Vila, J., Terencio, J., Guglietta, A. (2009). Decreased linezolid uptake in an in vitro-selected linezolid-resistant Staphylococcus epidermidis mutant. J Antimicrob Chemother 64: 990-992 [Abstract] [Full Text]  
  • Vidaillac, C., Leonard, S. N., Rybak, M. J. (2009). In Vitro Activity of Ceftaroline against Methicillin-Resistant Staphylococcus aureus and Heterogeneous Vancomycin-Intermediate S. aureus in a Hollow Fiber Model. Antimicrob. Agents Chemother. 53: 4712-4717 [Abstract] [Full Text]  
  • Schaadt, R., Sweeney, D., Shinabarger, D., Zurenko, G. (2009). In Vitro Activity of TR-700, the Active Ingredient of the Antibacterial Prodrug TR-701, a Novel Oxazolidinone Antibacterial Agent. Antimicrob. Agents Chemother. 53: 3236-3239 [Abstract] [Full Text]  
  • Liakopoulos, A., Neocleous, C., Klapsa, D., Kanellopoulou, M., Spiliopoulou, I., Mathiopoulos, K. D., Papafrangas, E., Petinaki, E. (2009). A T2504A mutation in the 23S rRNA gene responsible for high-level resistance to linezolid of Staphylococcus epidermidis. J Antimicrob Chemother 64: 206-207 [Full Text]  
  • Feng, J., Lupien, A., Gingras, H., Wasserscheid, J., Dewar, K., Legare, D., Ouellette, M. (2009). Genome sequencing of linezolid-resistant Streptococcus pneumoniae mutants reveals novel mechanisms of resistance. Genome Res 19: 1214-1223 [Abstract] [Full Text]  
  • Livermore, D. M., Mushtaq, S., Warner, M., Woodford, N. (2009). Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci. J Antimicrob Chemother 63: 713-715 [Abstract] [Full Text]  
  • Jones, R. N., Moet, G. J., Sader, H. S., Mendes, R. E., Castanheira, M. (2009). TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens. J Antimicrob Chemother 63: 716-720 [Abstract] [Full Text]  
  • Clark, C., Ednie, L. M., Lin, G., Smith, K., Kosowska-Shick, K., McGhee, P., Dewasse, B., Beachel, L., Caspers, P., Gaucher, B., Mert, G., Shapiro, S., Appelbaum, P. C. (2009). Antistaphylococcal Activity of Dihydrophthalazine Antifolates, a Family of Novel Antibacterial Drugs. Antimicrob. Agents Chemother. 53: 1353-1361 [Abstract] [Full Text]  
  • Giessing, A. M. B., Jensen, S. S., Rasmussen, A., Hansen, L. H., Gondela, A., Long, K., Vester, B., Kirpekar, F. (2009). Identification of 8-methyladenosine as the modification catalyzed by the radical SAM methyltransferase Cfr that confers antibiotic resistance in bacteria. RNA 15: 327-336 [Abstract] [Full Text]  
  • Kehrenberg, C., Cuny, C., Strommenger, B., Schwarz, S., Witte, W. (2009). Methicillin-Resistant and -Susceptible Staphylococcus aureus Strains of Clonal Lineages ST398 and ST9 from Swine Carry the Multidrug Resistance Gene cfr. Antimicrob. Agents Chemother. 53: 779-781 [Abstract] [Full Text]  
  • Shaw, K. J., Poppe, S., Schaadt, R., Brown-Driver, V., Finn, J., Pillar, C. M., Shinabarger, D., Zurenko, G. (2008). In Vitro Activity of TR-700, the Antibacterial Moiety of the Prodrug TR-701, against Linezolid-Resistant Strains. Antimicrob. Agents Chemother. 52: 4442-4447 [Abstract] [Full Text]  
  • Traczewski, M. M., Brown, S. D. (2008). Proposed MIC and Disk Diffusion Microbiological Cutoffs and Spectrum of Activity of Retapamulin, a Novel Topical Antimicrobial Agent. Antimicrob. Agents Chemother. 52: 3863-3867 [Abstract] [Full Text]  
  • Hawkey, P. M. (2008). Pre-clinical experience with daptomycin. J Antimicrob Chemother 62: iii7-iii14 [Abstract] [Full Text]  
  • Woodford, N., Afzal-Shah, M., Warner, M., Livermore, D. M. (2008). In vitro activity of retapamulin against Staphylococcus aureus isolates resistant to fusidic acid and mupirocin. J Antimicrob Chemother 62: 766-768 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mendes, R. E.
Right arrow Articles by Jones, R. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mendes, R. E.
Right arrow Articles by Jones, R. N.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»